BGB-B2033用于肝细胞癌的I 期 / II 期研究｜NCT06427941

一分钟看懂

这是一项关于肝细胞癌的I 期 / II 期研究，登记的药物或干预包括BGB-B2033；Tislelizumab；Bevacizumab，当前状态为招募中。登记地点显示中国合肥、重庆、福州、广州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。

BGB-B2033；Tislelizumab；Bevacizumab · I 期 / II 期

以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。

Anhui Provincial Hospital · 合肥
Chongqing University Cancer Hospital · 重庆
Mengchao Hepatobiliary Hospital of Fujian Medical University · 福州
Zhujiang Hospital of Southern Medical University · 广州
Nanfang Hospital of Southern Medical University · 广州
Guangxi Medical University Cancer Hospital Wuxiang Branch · 南宁
The Fourth Hospital of Hebei Medical University · 石家庄
Harbin Medical University Cancer Hospital · 哈尔滨
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology · 武汉
Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology · 武汉
Hunan Cancer Hospital · 长沙
The Affiliated Hospital of Xuzhou Medical University · 徐州
The Second Affiliated Hospital of Nanchang University · 南昌
The Second Affiliated Hospital of Nanchang Universityhongjiaozhou Branch · 南昌
Sichuan Cancer Hospital and Institute · 成都
The First Affiliated Hospital, Zhejiang University School of Medicine · 杭州
Lishui Central Hospital · 丽水
The First Affiliated Hospital of Wenzhou Medical University · 温州

1. Participants must have one of the following unresectable, locally advanced, or metastatic tumor types:
1. Hepatocellular carcinoma (HCC): Histologically or cytologically confirmed HCC that is either Barcelona Clinic Liver Cancer (BCLC) Stage C, or BCLC Stage B that is not amenable to, or has progressed after, loco-regional therapy and is not eligible for a cura
2. Alpha-fetoprotein (AFP)-producing gastric cancer (GC): Histologically confirmed GC with AFP \> 20 ng/mL in blood or tumor tissue positive for AFP by a validated immunohistochemistry (IHC) assay based on local or central testing.
3. Germ cell tumors: Histologically confirmed germ cell tumors including extragonadal yolk sac tumors (e.g., located in the mediastinum, vagina, brain, retroperitoneum), and non-dysgerminomas for which no further curative systemic treatment options exist.
4. Glypican-3 (GPC3)-positive squamous non-small cell lung cancer (NSCLC): Histologically confirmed GPC3-positive squamous NSCLC with prior exposure to a checkpoint inhibitor (CPI).
2. At least one evaluable lesion for dose escalation, and at least one measurable lesion for safety expansion, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
3. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1.
4. Adequate organ function as defined in the protocol.

请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。

登记号：NCT06427941；登记信息更新于 2026-09-16。